Furthermore, only ~14% (1/7) of tumors in BCL6-overexpressing/AICDA-knockout mice (tumor incidence = 7/29, or ~24%) possessed features of DLBCL, compared to ~69% (11/16) of tumors in BCL6-overexpressing/AICDA-normal mice (tumor incidence = 16/27, or ~59%)48. This evidence concerns the gene BCL6 and neoplasm.